Cargando…

Molecular classifications of gastric cancers: Novel insights and possible future applications

Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Garattini, Silvio Ken, Basile, Debora, Cattaneo, Monica, Fanotto, Valentina, Ongaro, Elena, Bonotto, Marta, Negri, Francesca V, Berenato, Rosa, Ermacora, Paola, Cardellino, Giovanni Gerardo, Giovannoni, Mariella, Pella, Nicoletta, Scartozzi, Mario, Antonuzzo, Lorenzo, Silvestris, Nicola, Fasola, Gianpiero, Aprile, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434387/
https://www.ncbi.nlm.nih.gov/pubmed/28567184
http://dx.doi.org/10.4251/wjgo.v9.i5.194
_version_ 1783237036247875584
author Garattini, Silvio Ken
Basile, Debora
Cattaneo, Monica
Fanotto, Valentina
Ongaro, Elena
Bonotto, Marta
Negri, Francesca V
Berenato, Rosa
Ermacora, Paola
Cardellino, Giovanni Gerardo
Giovannoni, Mariella
Pella, Nicoletta
Scartozzi, Mario
Antonuzzo, Lorenzo
Silvestris, Nicola
Fasola, Gianpiero
Aprile, Giuseppe
author_facet Garattini, Silvio Ken
Basile, Debora
Cattaneo, Monica
Fanotto, Valentina
Ongaro, Elena
Bonotto, Marta
Negri, Francesca V
Berenato, Rosa
Ermacora, Paola
Cardellino, Giovanni Gerardo
Giovannoni, Mariella
Pella, Nicoletta
Scartozzi, Mario
Antonuzzo, Lorenzo
Silvestris, Nicola
Fasola, Gianpiero
Aprile, Giuseppe
author_sort Garattini, Silvio Ken
collection PubMed
description Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2 (HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularly-driven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specific targeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses.
format Online
Article
Text
id pubmed-5434387
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-54343872017-05-31 Molecular classifications of gastric cancers: Novel insights and possible future applications Garattini, Silvio Ken Basile, Debora Cattaneo, Monica Fanotto, Valentina Ongaro, Elena Bonotto, Marta Negri, Francesca V Berenato, Rosa Ermacora, Paola Cardellino, Giovanni Gerardo Giovannoni, Mariella Pella, Nicoletta Scartozzi, Mario Antonuzzo, Lorenzo Silvestris, Nicola Fasola, Gianpiero Aprile, Giuseppe World J Gastrointest Oncol Field Of Vision Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2 (HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularly-driven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specific targeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses. Baishideng Publishing Group Inc 2017-05-15 2017-05-15 /pmc/articles/PMC5434387/ /pubmed/28567184 http://dx.doi.org/10.4251/wjgo.v9.i5.194 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Field Of Vision
Garattini, Silvio Ken
Basile, Debora
Cattaneo, Monica
Fanotto, Valentina
Ongaro, Elena
Bonotto, Marta
Negri, Francesca V
Berenato, Rosa
Ermacora, Paola
Cardellino, Giovanni Gerardo
Giovannoni, Mariella
Pella, Nicoletta
Scartozzi, Mario
Antonuzzo, Lorenzo
Silvestris, Nicola
Fasola, Gianpiero
Aprile, Giuseppe
Molecular classifications of gastric cancers: Novel insights and possible future applications
title Molecular classifications of gastric cancers: Novel insights and possible future applications
title_full Molecular classifications of gastric cancers: Novel insights and possible future applications
title_fullStr Molecular classifications of gastric cancers: Novel insights and possible future applications
title_full_unstemmed Molecular classifications of gastric cancers: Novel insights and possible future applications
title_short Molecular classifications of gastric cancers: Novel insights and possible future applications
title_sort molecular classifications of gastric cancers: novel insights and possible future applications
topic Field Of Vision
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434387/
https://www.ncbi.nlm.nih.gov/pubmed/28567184
http://dx.doi.org/10.4251/wjgo.v9.i5.194
work_keys_str_mv AT garattinisilvioken molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT basiledebora molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT cattaneomonica molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT fanottovalentina molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT ongaroelena molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT bonottomarta molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT negrifrancescav molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT berenatorosa molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT ermacorapaola molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT cardellinogiovannigerardo molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT giovannonimariella molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT pellanicoletta molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT scartozzimario molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT antonuzzolorenzo molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT silvestrisnicola molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT fasolagianpiero molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications
AT aprilegiuseppe molecularclassificationsofgastriccancersnovelinsightsandpossiblefutureapplications